MedTrace Logo

Immunotherapy With Bispecific CAR-T Cells for B-Cell Lymphoma, ALL and CLL

NCT03271515 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2021-01-20

No results posted yet for this study

Summary

This study aims to evaluate the safety, efficacy and duration of response of anti-CD19 anti-CD20 Bispecific Chimeric Antigen Receptor (CAR) redirected autologous T-cells in patients with high risk, relapsed CD19+ and CD20+ haematological malignancies.

Conditions

Interventions

BIOLOGICAL

anti-CD19 anti-CD20 Bispecific CAR-T

patients accept transfusion of anti-CD19 anti-CD20 Bispecific CAR-T cells.

Sponsors & Collaborators

  • Beijing Doing Biomedical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • li gangyi · Beijing Doing Biomedical Co., Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-01
Primary Completion
2022-03-01
Completion
2023-03-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03271515 on ClinicalTrials.gov